Highlight
This investigation highlights that nearly 40% of men with prostate cancer receiving concurrent androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) develop metabolic syndrome within the first year. The incidence is highest among those aged 70-79 years, with hypertension as the most prevalent metabolic complication. The study emphasizes metabolic monitoring beyond cancer management and suggests the need for proactive cardiometabolic interventions.
